Sellas Life Sciences

SELLAS™ Life Sciences to Present at 35th Annual JP Morgan Healthcare Conference

January 9th, 2017 at 10am PT – Westin St. Francis Hotel in San Francisco

HAMILTON, Bermuda and NEW YORK, NY, December 28, 2017 /PRNewswire/ — SELLAS Life Sciences Group (SELLAS or the Company), a late-stage biopharmaceutical company developing novel cancer immunotherapies for a broad range of cancer indications, today announced that it will be presenting at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis hotel in San Francisco.

Dr. Angelos Stergiou, Chief Executive Officer & Vice Chairman of the Board, will make a corporate and clinical presentation on Monday, January 9, 2017 at 10am PT.

About SELLAS’ WT1 Immunotherapeutic Anti-Cancer Treatment, galinpepimut-S

SELLAS’ novel late-stage clinical Wilms Tumor 1 (WT1) cancer immunotherapeutic treatment,  galinpepimut-S, is being developed to target hematologic cancers and solid tumors with an overexpression of the WT1 antigen, including acute myeloid leukemia (AML), mesothelioma (MPM), multiple myeloma, ovarian cancer, and multiple other cancers.  Galinpepimut-S, licensed from Memorial Sloan Kettering Cancer Center (MSKCC), will be entering into pivotal Phase 3 trials in AML and MPM during the first and second half of 2017, respectively, as well as other planned combination and monotherapy trials.

Wilms Tumor-1 (WT1) has been ranked by the National Cancer Institute (NCI) as the number 1 target for cancer immunotherapy due to its broad expression in a large number of cancers and cancer stem cells, while it is essentially absent in adult tissues.  Galinpepimut-S was specifically designed and has proven to stimulate a multipronged immune response against WT1 and works across different human leukocyte antigen (HLA) types.

Galinpepimut-S has shown highly encouraging Phase II survival data in AML, multiple myeloma, and mesothelioma.  The AML study showed a median overall survival (OS) of 61.8 months and in patients 60 years and older a median OS of 35 months; the MPM double-blind controlled trial a median OS of 24.8 months (galinpepimut-S) vs. 16.6 months (control arm).  Further recent data in multiple myeloma has shown an 86% OS rate after 18 months in patients with high-risk cytogenetics following stem cell transplantation with median OS and median PFS not reached yet.  SELLAS recently received orphan drug designations by the US FDA, as well as the EMA, for galinpepimut-S in AML and MPM; as well as fast track designation for AML and MPM by the US FDA.  The Phase I/II ovarian cancer trial (combination with BMS’s nivolumab (Opdivo®), is expected to have first clinical data available by Q2 2017.

 About SELLAS Life Sciences Group

SELLAS Life Sciences is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies and therapeutics for a broad range of cancer indications. The Company’s lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications. Galinpepimut-S is poised to enter pivotal Phase 3 clinical trials in patients with AML and Mesothelioma in the first and second half of 2017, respectively.

Galinpepimut-S also is in various development phases in multiple myeloma, ovarian cancer, and soon in other indications as monotherapy or in combination with other immuno-oncology agents.

SELLAS was founded in 2012 and is headquartered in Hamilton, Bermuda, with additional offices in New York City, NY.

Contact:

Jonathan Eckard, PhD, + 1 (917) 438-4350, jeckard@sellaslife.com

Jane Searle, +1 (212) 710-9686, jane.searle@mbsvalue.com

SOURCE SELLAS Life Sciences Group

About the Author